Paper41526596
Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RA+ T-cell depleted donor lymphocyte infusion.
Gopcsa L and 23 others. Geroscience, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RA+ T-cell depleted donor lymphocyte infusion. Papers, record 41526596. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41526596
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RA+ T-cell depleted donor lymphocyte infusion.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| Immunocompromised Host | Major topic |
| Interferon-gamma | Major topic |
| T-Lymphocytes | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Lymphocyte Transfusion | Major topic |
| Humans | |
| Female | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Leukocyte Common Antigens | |
| SARS-CoV-2 | |
| Adult | |
| Aged | |
| Hematopoietic Stem Cell Transplantation | |
| Lymphocyte Depletion |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| TKP2021-EGA-08 | 'Project number TKP2021-EGA-08 has been implemented with support from the National Research, Development, and Innovation Fund of Hungary, financed under the 'Thematic Excellence Program 2021' funding scheme'. | PubMed |
Source PubMed
References94
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34797216 | Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome. | Acta Microbiol Immunol Hung | 2021 | https://conductscience.org/library/papers/34797216 | PubMed |
| 2 | 40412763 | Advancing T-cell immunotherapy for cellular senescence and disease: Mechanisms, challenges, and clinical prospects. | Ageing Res Rev | 2025 | https://conductscience.org/library/papers/40412763 | PubMed |
| 3 | 36719907 | Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. | PLoS Med | 2023 | https://conductscience.org/library/papers/36719907 | PubMed |
| 4 | 36585293 | Donor selection for adoptive cell therapy with CD45RA- memory T cells for patients with coronavirus disease 2019, and dexamethasone and interleukin-15 effects on the phenotype, proliferation and interferon gamma release. | Cytotherapy | 2023 | https://conductscience.org/library/papers/36585293 | PubMed |
| 5 | 39294134 | Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. | Nat Commun | 2024 | https://conductscience.org/library/papers/39294134 | PubMed |
| 6 | 38593233 | Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients. | Blood Adv | 2024 | https://conductscience.org/library/papers/38593233 | PubMed |
| 7 | 37255929 | The ageing immune system as a potential target of senolytics. | Oxf Open Immunol | 2023 | https://conductscience.org/library/papers/37255929 | PubMed |
| 8 | 40100618 | Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective. | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/40100618 | PubMed |
| 9 | 40214453 | Recent Advances in Aging and Immunosenescence: Mechanisms and Therapeutic Strategies. | Cells | 2025 | https://conductscience.org/library/papers/40214453 | PubMed |
| 10 | 38321020 | Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment. | NPJ Aging | 2024 | https://conductscience.org/library/papers/38321020 | PubMed |
| 11 | 39125624 | Revealing the Hidden Impacts: Insights into Biological Aging and Long-Term Effects in Pauci- and Asymptomatic COVID-19 Healthcare Workers. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39125624 | PubMed |
| 12 | 39944414 | Virus-Specific T-Cell Therapy for the Management of Viral Infections in the Immunocompromised. | Transfus Med Hemother | 2025 | https://conductscience.org/library/papers/39944414 | PubMed |
| 13 | 36374737 | A Primer on Chimerism Analysis: A Straightforward, Thorough Review. | Lab Med | 2023 | https://conductscience.org/library/papers/36374737 | PubMed |
| 14 | 38212801 | Accelarated immune ageing is associated with COVID-19 disease severity. | Immun Ageing | 2024 | https://conductscience.org/library/papers/38212801 | PubMed |
| 15 | 36776371 | Selective depletion of naïve T cells by targeting CD45RA. | Front Oncol | 2022 | https://conductscience.org/library/papers/36776371 | PubMed |
| 16 | 40205403 | Clinical impact of concurrent autologous adoptive T cells immunotherapy in active COVID-19 infected cancer patients for chemotherapy. | Infect Agent Cancer | 2025 | https://conductscience.org/library/papers/40205403 | PubMed |
| 17 | 37240647 | Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study. | J Clin Med | 2023 | https://conductscience.org/library/papers/37240647 | PubMed |
| 18 | 38013358 | Immunosenescence and cancer: Opportunities and challenges. | Medicine (Baltimore) | 2023 | https://conductscience.org/library/papers/38013358 | PubMed |
| 19 | 36517599 | The WHO estimates of excess mortality associated with the COVID-19 pandemic. | Nature | 2023 | https://conductscience.org/library/papers/36517599 | PubMed |
| 20 | 38715113 | Evidence of SARS-CoV-2 convergent evolution in immunosuppressed patients treated with antiviral therapies. | Virol J | 2024 | https://conductscience.org/library/papers/38715113 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42713442 | Donor lymphocyte infusion as immune modulation after pediatric allogeneic transplantation. | Blood Immunol Cell Ther | 2026 | https://conductscience.org/library/papers/42713442 |
Source PubMed
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| PTPRC | 5788 | PubTator's text mining | https://conductscience.org/library/genes/5788 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41526596
GET https://conductscience.org/api/papers/v1/41526596/authors?page=2